Chronic Urticaria in Children Under 18 When Standard First-Line Antihistamine Has Not Achieved Full Control

This protocol applies to paediatric patients (under 18 years) with chronic urticaria whose initial treatment with a standard-dosed second-generation H1-antihistamine has not delivered complete symptom control. Management in children requires particular care around dosing, licensing, and established paediatric safety data.

Clinical Scenario

Patient age under 18 years with chronic urticaria. Treatment decisions must account for licensing status, weight- and age-adjusted dosing, and the available evidence base for each option in children.

Previous Treatment — Goals Not Reached

First-line therapy with a standard-dosed second-generation H1-antihistamine (using an agent with proven paediatric efficacy and safety) did not achieve the required treatment goals: a continuous urticaria activity score (UAS) of 0 and a urticaria control test (UCT) of 16. This failure to reach complete symptom control triggers escalation to the next protocol step.

Next-Step Approach

The protocol moves to a modified use of a second-generation H1-antihistamine, applied with specific caution given the limited evidence in the paediatric population.

The complete protocol — including the specific strategy, all age- and weight-related considerations, and further options — is available in the full regimen →

Instant Access to Structured Evidence-Based Regimens

References

We suggest using the same treatment algorithm with caution (e.g., according to licensing status, experience for use in children, weight-and age-adjusted dosage) in children with chronic urticaria.

All further steps should be based on individual considerations and be taken carefully as updosing of antihistamines and further treatment options are not well studied in children.

DOI: 10.1111/all.70210

View source ↗